Ana Dinca is a principal scientist in antibody discovery, currently working at Pfizer since 2024. They previously held the role of senior scientist at Seagen and led the antibody discovery team at SystImmune, where they successfully identified high-affinity binders for cancer targets. Ana completed a PhD at the University of Washington, where they developed enzyme replacement therapy for Barth Syndrome, leading to a patent. Their extensive experience includes postdoctoral research at Fred Hutch and clinical trial coordination at the University of California, San Diego.
This person is not in the org chart
This person is not in any teams
This person is not in any offices